Skip to main content

Commentary: The small-molecule 'penalty' is a threat to Mass. biotech sector

The Inflation Reduction Act inadvertently introduced a change in drug-development incentives that could result in distorted decisions about which treatments get developed.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.